Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

William Blair Initiates Coverage On NewAmsterdam Pharma with Outperform Rating

William Blair analyst Matthew Phipps initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform rating.
byBenzinga Newsdesk
December 19, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

William Blair analyst Matthew Phipps initiates coverage on NewAmsterdam Pharma (NASDAQ:NAMS) with a Outperform rating.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts